针对Clostridioides difficile感染预防的新型生物治疗产品的进展
Thomas Lavoie1,2, Haley J Appaneal1,3,2, Kerry L LaPlante1,2,3,4,5
1Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
概括
人的肠道微生物组显著影响健康和疾病. 诸如便微生物种移植 (FMT) 和活生物治疗等干预措施在通过恢复肠道微生物平衡来治疗和预防Clostridioides difficile感染 (CDI) 方面表现有前途.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 人类微生物群,特别是肠道微生物群,在生理过程和整体健康中起着至关重要的作用.
- 肠道微生物组成不平衡的失生症与病变发生有关,包括Clostridioides difficile感染 (CDI).
- 目前对CDI的抗生素治疗往往无法解决失生症,并可能加剧微生物破坏.
结论:
- 恢复肠道微生物平衡对于有效的CDI治疗和预防至关重要.
- 基于便微生物群的产品为肠道恢复和减少CDI复发提供了显著的潜力.
- 进一步了解微生物组在CDI中的作用将推动未来疗法的开发.
更多相关视频
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
10.1K
06:51Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
12.5K
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143